Cytomorphology of Chimeric Antigen Receptor T-Cells (CAR-T)

Main Article Content

Eugenio Galli
Silvia Bellesi
Marcello Viscovo
Federica Sorà
Stefan Hohaus
Nicola Piccirillo
Luca Laurenti
Patrizia Chiusolo
Valerio De Stefano
Simona Sica
Gina Zini


Chimeric antigen receptor T cells, CAR-T, cytomorphology, immunotherapy, cell therapy


Chimeric antigen receptor (CAR) T cells represent one of the newest frontiers of cell therapy. Their application currently involves relapsed/refractory aggressive B cell lymphoma and leukemia as a standard of care, while several studies are exploring CAR-T to treat multiple myeloma and other hematological malignancies. Here we describe the cytomorphology of CAR-T collected from the leftovers of infusion bags, and therefore before the encounter with the antigen, with, among others, a peculiar population of giant lymphoid cells with blastoid features and hypertrophic centrosome.


Download data is not yet available.

Abstract 525
PDF Downloads 248
HTML Downloads 85


1. Magnani CF, Gaipa G, Lussana F, et al. Sleeping Beauty–engineered CAR T cells achieve antileukemic activity without severe toxicities. J Clin Invest . 2020 Nov 2 130(11):6021–33.
2. Kupfer A, Swain SL, Janeway CA, Singer SJ. The specific direct interaction of helper T cells and antigen-presenting B cells (microtubule organizing center/Golgi apparatus/immunofluorescence). Vol. 83, Immunology. 1986.
3. Hui KL, Upadhyaya A. Dynamic microtubules regulate cellular contractility during T-cell activation. Proc Natl Acad Sci U S A 2017 May 23;114(21):E4175–83
4. Brooks S, Frey N, Porter D, June C, Lacey S, Bagg A. The cytological features of CAR(T) cells. Vol. 175, British Journal of Haematology. Blackwell Publishing Ltd; 2016. p. 366.
5. Han X, Wang C, Zhou J. Chimeric antigen receptor T (CAR-T) cells present with reactive and pleomorphic morphology in bone marrow. Vol. 94, American Journal of Hematology. Wiley-Liss Inc.; 2019. p. 1297–8.
6. Faude S, Wei J, Muralidharan K, et al. Absolute lymphocyte count proliferation kinetics after CAR T-cell infusion impact response and relapse. Blood Adv. 2021 Apr 27;5(8):2128–36.